Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

SLNBullishEarningsShort Term

High materiality9/10

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

StockNews.AIAug 10, 7:15 AM EDT2 sources

Trading thesisImportance 9/10

Bullish: expect re-rating on SANRECO durability data and 2027 INDs within 6–12 months.

AI summary

What happened and why it matters

Silence Therapeutics posted Q2 2026 results with progress across its divesiran program (SANRECO Phase 2 dosing completed in 48 PV patients) and the ANGPTL3 program SLN312 with AstraZeneca, plus IND timing for SLN365/SLN098 in 2027. Cash stood at $72.1 million; R&D fell to $9.1 million. Key catalysts—SANRECO durability data and 2027 INDs—could drive near-term upside over the next 6–12 months.

SANRECO Phase 2 dosing completed; topline data expected 2026–2027.
IND filings for SLN365 and SLN098 anticipated in 2027.
AZN ANGPTL3 collaboration: Phase 1 shows dose-dependent lipid reductions.
Cash runway supports upcoming data catalysts; Q2 cash $72.1M.

Sentiment rationale

The combination of SANRECO Phase 2 dosing completion with durable PV data, plus 2027 IND timelines for SLN365/SLN098 and AZN collaboration implications, provides multiple price-relevant catalysts within 6–12 months. Historically, biotech name-specific data readouts and strong collaboration news tend to drive multiple expansion and re-rating when cash burn improves and late-stage reads look favorable.

Key facts

01
Phase 2 SANRECO divesiran dosing completed; 48 PV patients. EHA data show durable efficacy.
02
Divesiran data hints at best-in-class PV profile.
03
IND timing for SLN365 and SLN098 expected in 2027.
04
Cash and equivalents $72.1 million; Q2 net loss $12.3 million.
05
R&D expense down to $9.1 million; zerlasiran Phase 3 prep completed.

Earnings

Category: Earnings; The article centers on Q2 2026 results and pipeline/partnership catalysts, aligning with Corporate/biotech earnings disclosures and near-term clinical development milestones.